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Background: Individuals with Down Syndrome (DS) are reported to experience early onset of brain aging.
However, it is not well understood how pre-existing neurodevelopmental effects versus neurodegenerative
processes might be contributing to the observed pattern of brain atrophy in younger adults with DS. The aims of
the current study were to: (1) to confirm previous findings of age-related changes in DS compared to adults with
typical development (TD), (2) to test for an effect of these age-related changes in a second neurodevelopmental
disorder, Williams syndrome (WS), and (3) to identify a pattern of regional age-related effects that are unique to DS.
Methods: High-resolution T1-weighted MRI of the brains of subjects with DS, WS, and TD controls were segmented,
and estimates of regional brain volume were derived using FreeSurfer. A general linear model was employed to test
for age-related effects on volume between groups. Secondary analyses in the DS group explored the relationship
between brain volume and neuropsychological tests and APOE.
Results: Consistent with previous findings, the DS group showed significantly greater age-related effects relative to
TD controls in total gray matter and in regions of the orbitofrontal cortex and the parietal cortex. Individuals with
DS also showed significantly greater age-related effects on volume of the left and right inferior lateral ventricles
(LILV and RILV, respectively). There were no significant differences in age-related effects on volume when comparing
the WS and TD groups. In the DS group, cognitive tests scores measuring signs of dementia and APOE ε4 carrier
status were associated with LILV and RILV volume.
Conclusions: Individuals with DS demonstrated a unique pattern of age-related effects on gray matter and
ventricular volume, the latter of which was associated with dementia rating scores in the DS group. Results may
indicate that early onset of brain aging in DS is primarily due to DS-specific neurodegenerative processes, as
opposed to general atypical neurodevelopment.
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It has been suggested that individuals with Down syn-
drome (DS) experience early onset, or perhaps acceler-
ated, brain aging as evidenced by significant age-related
reduction in brain volume, but to date, it is not known
whether this is an effect of the accumulated neurotoxic
pathology evident in DS or a pre-existing feature of
atypical neurodevelopment [1]. In the current study, we
aimed to dissociate the contribution of neurodevelop-
ment versus neurodegeneration in regional brain vol-
ume in DS. We compared a wide age range of adults
with DS to adults with a different neurodevelopmental
disorder, Williams syndrome (WS), and we also com-
pared both neurodevelopmental disorders to a typically
developing (TD) control group.
Etiology and presentation of Down syndrome and
Williams syndrome
DS is a neurodevelopmental disorder caused by the pres-
ence of three copies of chromosome 21 (trisomy 21). It
occurs in one in every 691 live births in the US [2] and
is the most common genetic cause of intellectual disabil-
ity [3,4]. The degree of cognitive impairment associated
with DS ranges from mild to severe, with the mean IQ
of 50, or moderate intellectual disability [4]. Individuals
with DS exhibit deficits in language, verbal short-term
memory, and explicit long-term memory; whereas visuo-
spatial short-term memory, associative learning, and im-
plicit memory are relatively preserved [5]. Advances in
the treatment of medical comorbidities, such as heart
defects and digestive malformations, have resulted in
dramatic improvements in life expectancy for individuals
with DS living in the US, rising from nine years in the
early-twentieth century [6] to nearly 60 years in 2010 [7].
Although individuals with DS present with a unique cog-
nitive and behavioral profile, they do share some basic
characteristics with individuals who have WS.
WS is a neurodevelopmental disorder caused by the
hemizygous deletion of 26 to 28 genes on chromosome
7 [8]. The prevalence of WS is one in every 7,500 live
births [9]. As with DS, WS is associated with intellectual
disability. The average IQ for individuals with WS is ap-
proximately 50 to 60, indicating mild to moderate intel-
lectual disability [10,11]. The WS cognitive profile is
characterized by deficits in visuospatial and implicit
memory as well as strengths in language, verbal short-
term memory, face and object recognition, and music
processing skills [12-16]. In addition, individuals with
WS often demonstrate increased non-social anxiety and
phobias, paired with hypersociability and heightened
empathy [17-19]. Similar to individuals with DS, per-
sons with WS have experienced a significant increase in
mean life expectancy following advances in treatment
for medical comorbidities, particularly cardiac defects.There is very little literature on aging or life expectancy
in WS, but there are documented cases of persons with
WS who lived to be 70 years old [20].
Brain morphometry in Down syndrome and
Williams syndrome
Children and young adults with DS or WS have an overall
smaller brain volume compared to TD individuals of simi-
lar age [21]; however the specific brain areas that show sig-
nificant volumetric differences compared to TD are distinct
for each of the neurodevelopmental disorders. Individuals
with DS have smaller frontal, amygdalar, and cerebellar vol-
umes compared to TDs; whereas individuals with WS have
smaller midbrain, thalamic, basal ganglia, and occipital and
superior parietal lobe volumes compared to age-matched
TDs [22,23]. It is important to also note that individuals
with DS have an increase in parahippocampal volume and
relatively preserved lenticular nuclei, basal ganglia, and oc-
cipital lobe volumes [4,5,24]. Young adults with WS have
relatively preserved frontal lobe, anterior cingulate, superior
temporal and fusiform gyrus, amygdalar, and cerebellar vol-
umes compared to TDs [5,22,24].
In addition to the pre-existing smaller volumes of frontal,
amygdalar and cerebellar structures, older adults with
DS (>50 years of age) have been shown to also have
smaller whole prefrontal, posterior cingulate, hippocam-
pal, and parahippocampal volumes when compared to
age-matched TD adults [5]. Studies have shown that as
individuals with DS age, they exhibit a similar pattern of
neurodegeneration to that seen in the early stages of
Alzheimer’s disease in the general population, in which
the earliest neuropathological changes present in the
medial-temporal lobe and progress to neocortex and
subcortical regions [25]. However, in individuals with
DS these neuropathological changes occur at a much
younger age compared to the general population, which
has been attributed to early onset, or perhaps acceler-
ated, brain aging [1].
At present, very few studies have assessed changes in
brain morphology in older adults with WS [26]. Studies
have shown an overall 15% smaller brain volume in adults
with WS between 19 and 52 years of age compared to
age-matched TD controls [20,21]; however, they found no
difference in the magnitude of this finding between older
individuals with WS and a group of younger persons with
WS, suggesting the effect might not be age-related [20].
Study aims
The aims of the current study were to: (1) confirm pre-
vious findings of age-related brain changes in DS versus
TD, (2) document any age-related differences in brain vo-
lume seen in WS versus TD, and (3) test for age-related ef-
fects that are unique to DS. If the changes seen in DS are
primarily due to DS-specific neurodegenerative processes,
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related effects would be greater than those in the TD and
WS groups. If, however, these changes are instead associ-
ated with a non-specific vulnerability due to atypical neuro-
development, then we would hypothesize that both DS and
WS groups would show greater age-related differences as




The current study included 14 DS adults (7 males; mean
age 39; age range: 19 to 63), 41 WS adults (24 males;
mean age 26, age range: 16 to 58), and 82 TD adults (40
males; mean age 36, age range: 18 to 90). Adults with
DS or TD were recruited using flyers and website post-
ings with Institutional Review Board-approved language
targeting adults over 18 years of age. For adults with DS,
we further recruited from local and regional educational
centers for individuals with intellectual disabilities,
community-based assisted living centers, caregiver sup-
port groups, and employment assistance programs. Par-
ticipants with WS were recruited through the annual
Academy of Country Music Lifting Lives Music Camp,
which is organized by the Vanderbilt Kennedy Center for
Research on Human Development. All participants with
WS or DS exhibited the physical, cognitive, and behav-
ioral profile of WS and DS, respectively, and they previ-
ously had received a clinical diagnosis of the disease.
Adults with typical neurodevelopment were ascertained
either as age-matched controls for study participants
with WS or as healthy older adults who served as con-
trols for a general population study of age-related cogni-
tive impairment. The three groups were tested for
differences in age and sex, using an independent samples
t-test and a chi-square test, respectively. Demographic
characteristics along with their corresponding statistical
values are detailed in Table 1.Table 1 Sample demographics for participants with Down syn
developing (TD) controls
DS (N = 14) TD (N = 82) WS (N
N % N % N
Male sex 7 50 40 49 24
Range Mean SD Range Mean SD Range M
Age (years) 19 to 63 39 13 18 to 90 36 18 16 to 58
Range Median SD
DLD-SCS 0 to 21 0.5 8
DLD-SOS 0 to 18 5 5
SD = standard deviation, N = number or count, % = percentage of subjects in the gr
test of independence statistic.Participants with TD and caregivers of individuals with
DS or WS gave informed consent, while participants
with DS or WS gave informed assent for this study.
All study procedures were approved by the Vanderbilt
University Institutional Review Board.
Magnetic resonance imaging acquisition
Adults participated in a magnetic resonance imaging
(MRI) scan in a Philips Achieva 3-Tesla scanner (Philips
Medical Systems, Inc., Best, Netherlands) using an eight-
channel SENSE head coil, housed in the Vanderbilt
University Institute of Imaging Science (Nashville, TN,
USA). High-resolution three-dimensional anatomical
T1-weighted MRI images were acquired using a turbo
field echo sequence with full brain coverage and the fol-
lowing parameters: field of view = 256 × 256 mm2; in plane
voxel resolution = 1 × 1 mm2; repetition time = 8.9 ms;
echo time = 4.6 ms; flip angle = 8°; slice thickness = 1 mm
and 170 slices with no slice gap.
Neuroimaging analysis
To parcellate the brain into cortical and subcortical tis-
sue classes and derive quantitative estimates of brain
volume, we used an automated, non-biased atlas-based
Bayesian segmentation procedure, applied in FreeSurfer
v.5.0 (http://surfer.nmr.mgh.harvard.edu/) [27]. FreeSurfer
preprocessing for volumetric T1-weighted images in-
cluded: brain extraction and removal of non-brain tissue
using a hybrid watershed/surface deformation procedure
[28]; automated spatial transformation and white matter
segmentation of subcortical volumetric structures [29];
intensity normalization, tessellation of gray matter/white
matter boundary and automated topology correction [30];
and surface deformation following intensity gradients
to optimally place gray matter/white matter and gray
matter/cerebrospinal fluid borders at the location where
the greatest shift in intensity defines the transition to
the other tissue class [27]. Image outputs from eachdrome (DS), Williams syndrome (WS), and typically
Group contrasts
= 41) DS versus WS versus TD
% χ2 P-value
59 1.89 0.39
DS versus TD WS versus TD DS versus WS
ean SD t P-value t P-value t P-value
26 8 0.61 0.54 −3.44 1.0E-03 4.31 7.1E-05
oup corresponding to the preceding count, t = t-statistic, and χ2 = chi-square
Koran et al. Journal of Neurodevelopmental Disorders 2014, 6:8 Page 4 of 11
http://www.jneurodevdisorders.com/content/6/1/8stage of FreeSurfer processing were visually inspected
independently by three imaging analysts (CME, MEK).
Only images that passed quality control by both ana-
lysts were used; seven DS, five WS, and five TD adults
were not included in the analysis because of failure to
pass quality control, leaving a total of 14, 58 and 81
adults in each category, respectively. Quantitative esti-
mates of volume were derived in a large set of spatially
distinct region of interests (ROIs) that covered the en-
tire brain, as specified in the Desikan atlas [31]. This
atlas includes parcellations of gray and white matter
and segmentations of subcortical gray matter, and also
includes summary volumes (that is total cortex volume).
Parcellations of the gray and white matter and segmenta-
tions of subcortical gray matter were included, along with
two summary measurements of total gray and total white
matter (see Additional file 1: Tables S1a and b for
complete list of ROIs included and those excluded, re-
spectively). Total intracranial volume (ICV) was also
estimated in FreeSurfer, and all ROI measures were
normalized to ICV for subsequent analyses.
Genotyping
Adults with DS had blood drawn for DNA, which was
directly genotyped for APOE using pre-made TaqMan
SNP genotyping assays from Applied Biosystems (ABI;
Foster City, CA, USA). Negative controls (no template)
and positive controls (DNA samples with known genotypes
from Coriell Institute for Medical Research, Camden, NJ,
USA) were included on the plate for assay validation. Since
genotyping was performed in a research laboratory that is
not CLIA-certified, genotyping results were not returned
to patients or their clinicians.
Cognitive testing
For all participants with Down syndrome, we conducted
a comprehensive battery of cognitive and neuropsycho-
logical tests (see Additional file 1: Table S2), including
the Dementia Questionnaire for People with Learning
Disabilities (DLD; Harcourt Assessment, Amsterdam,
Netherlands, 2006) [32]. Although there is no ‘gold stan-
dard’ for assessing dementia in individuals with DS, stud-
ies have shown that the DLD is useful in the differential
diagnosis of dementia [33,34]. The DLD is a 50-item
questionnaire that consists of eight subtests (short-term
memory, long-term memory, and spatial and temporal
orientation, speech, practical skills, mood, activity and
interest, and behavioral disturbance) that assess both
cognition and social skills. For each item, a score of 0
indicates no deficit, 1 indicates moderate deficit, and 2
indicates severe deficit. The sum of cognitive scores
(SCS) is calculated from the short-term memory, long-
term memory, spatial and temporal orientation subtests,
and the range of possible scores for the DLD-SCS is 0 to44. The sum of social scores (SOS) is calculated from
the speech, practical skills, mood, activity, and interest
and behavioral disturbance subtests, and the range of
possible scores for the DLD-SOS is 0 to 60. Higher
scores on each subtest indicate greater impairment. A
masters-level study coordinator with training and ex-
perience in cognitive and neuropsychological assess-
ment administered the DLD. Complete results of
neuropsychological testing for the DS participants, as
well as APOE ε4 carrier status, can be seen in Additional
file 1: Table S2. We also note that none of the partici-
pants with DS were taking anti-depressants, anti-
psychotics or cholinesterase-inhibitors, which could
confound cognitive testing results, although one person
was taking the anti-convulsant ‘Lamictal,’ which is a so-
dium channel blocker.
Statistical analysis
Our first two aims were to (1) confirm previous findings
of early age-related changes in DS compared to TD and
(2) test for a comparable effect in WS relative to TD. In
order to approach these aims, we implemented a general
linear model in R (http://www.R-project.org) across 103
separate regions of interest:
ðICV‐corrected volume of each ROI ¼
Groupþ Ageþ Sexþ Group  Ageð ÞÞ
Group status was dummy-coded in the regression model
with TD set as the reference category. Thus, our model
included two group main effects (DS as 0 or 1 and WS
as 0 or 1) and two interaction terms: age × DS and age ×
WS which statistically compare the age-related slopes of
regional volume between the respective diagnostic cat-
egory and TD controls. This method and a three cat-
egory method in ANCOVA are statistically equivalent
[35]. However, in the linear regression method used here,
the t-tests based on dummy-coded variables directly test
the alternative hypothesis that the coded group differs
from the reference group (in this case, TD controls),
which aids in the interpretation of results.
Sex was coded as a binary discrete variable (male as 0;
female as 1). A Bonferroni corrected significance thresh-
old of P < 4.85 × 10−4 was applied to the interaction
terms in order to correct for the 103 ROIs tested (see
Additional file 1: Table S2a for list of ROIs tested). A
post hoc analysis was conducted to determine the sensi-
tivity of results due to outliers. Outliers were defined as
adults with ICV-corrected total gray matter volume out-
side of the grand mean ± two standard deviations (calcu-
lated in SPSS, www.ibm.com/software/analytics/spss/).
A final aim was to test for age-related effects unique
to DS. The same general linear model was used (ICV-
corrected volume of each ROI = Group + Age + Sex +
Figure 1 Representative T1-weighted MRI for each group (Down syndrome (DS), typically developing (TD), and Williams syndrome
(WS)). The subjects are 35, 36, and 38 years old respectively. The inferior lateral ventricles can be seen as hypo-intense spaces around the
hippocampus in the temporal lobes.
Table 2 Brain regions where the relationship between
age and volume was significantly different between
participants with Down syndrome (DS) versus typical
development (TD)
Region of interest Group (DS versus TD) × Age Interaction
t P-value Difference in R2
LILV 4.31 3.25E-05 0.09
RILV 4.05 9.03E-05 0.10
Left superior parietal −4.02 1.01E-04 0.08
Left inferior parietal −3.97 1.23E-04 0.08
Left pars orbitalis −3.82 2.11E-04 0.07
Right post central gyrus −3.67 3.58E-04 0.07
Difference in R2 is reported for full model that included age, sex, group and
groupxage, versus the reduced model that included age, sex, and group.
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jects (WS = 0 and DS = 1). A Bonferroni correction was
applied to determine the significant interaction terms, and
again a post hoc analysis was performed after removing
statistical outliers.
Secondary exploratory analyses
In order to further explore age-related volume that is spe-
cific to DS, we performed linear regression to test for an
association between brain volume and other cognitive and
genetic risk factors. Since DLD and genotyping data were
only collected for participants with DS, analyses were re-
stricted to the DS group. To control for Type I error, we
restricted our analysis to brain regions that showed sig-
nificant age-related effects, which were stronger in DS
relative to TD and WS. Predictors included age, sex,
and the variable of interest. For each ROI, we tested for
an association with DLD-SOS or DLD-SCS as the con-
tinuous variable of interest. We report the t-statistic for
the variable of interest (DLD-SOS or DLD-SCS), along
with its unadjusted P-value, and we report the change in
R2 comparing the full model with the variable of interest
to the reduced model with only age and sex.
Next we performed an exploratory analysis to deter-
mine the relationship between APOE ε4 carrier status
and age-related volume effects in DS. The absence/pres-
ence of APOE ε4 alleles was coded as 0/1, respectively.
We report the unadjusted P-value of the APOE term and
the change in R2 for the full model with APOE to the re-
duced model with only age and sex as predictors.
Results
Example T1-weighted MR images for each group can
be seen in Figure 1. Our first analysis aimed to (1) rep-
licate previous findings of age-related effects on brain
in DS and (2) test for similar effects in WS. Consistent
with previous findings, the DS group showed significantlygreater age-related effects on gray matter volume relative
to TD controls in the regions of the orbitofrontal cortex
(the left pars orbitalis) and the parietal cortex (the left
superior parietal lobe, the left inferior parietal lobe and
the right post central gyrus; Table 2, Additional file 1:
Table S3; Figure 2). Individuals with DS also showed sig-
nificant age-related effects on volume of the left and
right inferior lateral ventricles (LILV and RILV, respec-
tively, Figure 3). In contrast, there were no significant
differences in age-related volume between WS and TD
controls. The summary measurements of total white
matter and total gray matter volumes were also ana-
lyzed, and the DS group showed greater age-related ef-
fects on total gray matter volume (unadjusted P = .007)
while there was no significant effect in the total white
matter volume measure (P = .055).
Our second analysis compared age-related volume in DS
to age-related volume in WS (Table 3; Additional file 1:
Table S4). The DS group showed a stronger relationship
between age and volume for the left and right lateral
ventricles relative to WS, and this difference remained
Figure 2 Regional brain volumes normalized to total intracranial volume (ICV) are plotted in relationship to age across the three
subject groups (Down syndrome (DS) in red, typical development (TD) in green, and William syndrome (WS) in blue) in (a) left inferior
parietal lobe, (b) left pars orbitalis, (c) left superior parietal lobe, and (d) right post central gyrus.
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of age versus volume for all significant ROIs are presented
in Figures 2 and 3.
To investigate whether outliers were driving the ob-
served effects, we removed the participants whose ICV-corrected total gray matter volume was outside of two
standard deviations of the grand mean, and we repeated
our analyses. One DS subject and four WS adults were
removed, but no outliers were identified for the TD
group. For the first regression analysis, the interaction
Figure 3 Regional brain volumes normalized to total intracranial volume (ICV) are plotted in relationship to age across the three
subject groups (Down syndrome (DS) in red, typical development (TD) in green, and William syndrome (WS) in blue) in: (a) left inferior
lateral ventricle (LILV) and (b) right inferior lateral ventricle (RILV).
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relationship between volume and age between DS and
TD groups, remained significant after Bonferroni correc-
tion for the left superior parietal lobe, and in all other
ROIs found significant in primary analyses, the interaction
term was nominally significant at an unadjusted P < .05.
For the second regression analysis, the interaction model
term comparing age-related effects in volume between the
DS and WS groups remained significant after Bonferroni
correction for the right lateral ventricle, and for the left
lateral ventricle, the interaction term was nominally
significant at an unadjusted P < .05. No additional ROIs
reached Bonferroni significance after outliers were re-
moved in either analysis. These results are presented in
Additional file 1: Tables S5a and S5b and Additional
file 1: Figure S1.Table 3 Brain regions where the relationship between
age and volume was significantly different between
participants with Down syndrome (DS) versus Williams
syndrome (WS)
Region of interest Group (DS versus WS) × Age Interaction Term
t P-value Difference in R2
Right lateral ventricle 4.42 8.64E-05 0.14
Left lateral ventricle 3.75 1.35E-04 0.12
The right lateral ventricle association was significant after
Bonferroni correction.In secondary analyses, we explored the relationships
between brain volume in the eight significant ROIs re-
ported above and the DLD-SOS score, the DLD-SCS score,
and APOE status in DS adults using linear regression. Full
results are presented in Table 4. DLD-SCS and -SOS scores
were significantly intercorrelated (r2 = .770, P = .002) and
explained similarly high rates of variability in regional brain
volume, beyond that explained by the reduced model
including age and sex. DLS-SCS scores explained 21
and 25% of the variance in LILV and RILV volume, respect-
ively (P = .042 and P = .031; Additional file 1: Figure S2).
DLD-SOS scores explained 38% of variance of both the
LILV and RILV volumes (P = .001 and P = .003; Additional
file 1: Figure S3). DLD-SOS was also nominally associated
with the overall right ventricular volume (P = .029) and
explained 15% of right ventricular volume variance. APOE
explained 22% of the variance in LILV and RILV volume
(P = .026 and .033; Additional file 1: Figure S4).
Thus, in summary, all three variables were nominally
associated with LILV and RILV volume (P < .05), and the
association between DLD-SOS and RILV volume was
significant after Bonferroni correction. However, after
the one DS outlier was removed, only the relationships
between DLD-SCS and RILV and between DLD-SOS
and LILV remained even nominally significant (P = .037
and .009, respectively). Notably, the removed subject
was one of three adults who had an APOE ε4 allele.
Table 4 Relationship between Volume and Dementia Questionnaire for People with Learning Disabilities (DLD) sum of
cognitive scores (SCS) and sum of social scores (SOS) or APOE in brain regions showing a correlation with age in Down
syndrome participants
Region of interest DLD-SCS DLD-SOS APOE
t P-value Difference in R2 t P-value Difference in R2 t P-value Difference in R2
LILV 2.37 0.042 0.21 4.72 0.001 0.38 2.61 0.026 0.22
RILV 2.56 0.031 0.25 4.01 0.003 0.38 2.47 0.033 0.22
Left superior parietal −1.32 0.219 0.06 0.41 0.693 0.01 −1.06 0.315 0.04
Left pars orbitalis −1.66 0.131 0.08 −1.32 0.220 0.06 −1.23 0.247 0.10
Left inferior parietal −1.21 0.256 0.07 −1.59 0.146 0.10 −1.87 0.091 0.06
Right post central gyrus −0.54 0.604 0.01 −1.11 0.294 0.05 0.05 0.961 0.00
Left ventricle 0.57 0.582 0.01 2.06 0.069 0.13 1.45 0.178 0.07
Right ventricle 0.91 0.386 0.03 2.59 0.029 0.15 1.78 0.105 0.08
Italicized P-values indicate nominal association at uncorrected P < .05. The Difference in R2 values indicates the difference in the variability in the region of interest
(ROI) volume explained by the full model that included the predictor of interest (DLD-SCS, DLD-SOS, or APOE), compared to that explained by the reduced model
with only age and sex as predictors.
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The first aim of the current study was to confirm previ-
ous findings of age-related brain changes in DS [1]. In
previous studies, adults with DS had significantly stronger
relationships between age and volume in the frontal, par-
ietal, and temporal lobes, and the lateral ventricles [1]. We
replicated these findings in the frontal lobe (specifically,
the left pars orbitalis gyri frontalis inferioris), the parietal
lobe (specifically, the left superior and left inferior parietal
cortices and the right post central gyrus), and in the lateral
ventricles (specifically, the LILV and RILV).
Interestingly, atrophy in these gray matter regions and
dilation of the ventricles may be explained by the link
between DS and Alzheimer’s disease (AD). Individuals
with DS are at a greatly increased risk of developing AD,
with up to 70 percent developing dementia by the age of
70 [36]. In fact, adults with DS account for up to 60% of
individuals with developmental disabilities who exhibit
signs of AD [37]. The risk for AD in DS is primarily re-
lated to triplication of the amyloid precursor protein
(APP), which is on chromosome 21 [38]. However, one’s
genotype at the apolipoprotein E (APOE) gene, whose
protein product is involved in the processing of amyloid
beta isoforms, has also been shown to modulate risk for
developing AD in the DS population [39,40]. Postmor-
tem studies have revealed that plaque load in adults with
DS increases with age: by 40 years of age, nearly all indi-
viduals with DS have amyloid beta plaques in the brain
[41], and this characteristic feature of AD has neurotoxic
effects that can lead to neurodegeneration and loss in brain
volume [42]. More specifically, both the frontal and parietal
lobes have shown increased amyloid load as measured by
positron emission tomography (PET) in participants with
DS [43]. Therefore, the age-related effects detected in this
study may be due to the early-onset of neurotoxic effects
related to increases in amyloid load in adults with DS.Age-related volume in DS relative to WS adults was sig-
nificant in the left and right total lateral ventricles, even
after Bonferroni correction for multiple comparisons, and
there was a stronger relationship between age and volume
in the inferior lateral ventricles in the DS group compared
to the TD group. These results are particularly interesting
given the high prevalence of AD in DS and the association
between ventricular dilation and AD. Volume of the lat-
eral ventricles has repeatedly shown a relationship to AD
status and disease progression in the general population
[44-47]. The lateral ventricles normally dilate over time
with age, as brain tissue volume decreases, but in patients
with mild cognitive impairment (MCI) or AD, the rate of
ventricular dilation is much greater than in the general
aging population [48]. The inferior lateral ventricles are
surrounded by subcortical gray matter structures, and
these structures, particularly the hippocampus, entorhinal
cortex, and amygdala, accumulate amyloid plaques and
exhibit atrophy in AD [48,49] and DS [50-54]. Since ven-
tricular dilation is cumulatively and inversely reflective of
atrophy of these surrounding structures [55], and since we
found this strong relationship between age and ventricular
volume was not present in WS, these results may be re-
flective of the neurodegenerative effects of AD pathology
on the structures surrounding the ventricles.
We also investigated whether, similar to the DS group,
the WS group experienced greater age-related effects
compared to the TD group, but we did not find evidence
to support this hypothesis. This is in line with the one
previously reported finding of aging WS adults [20].
However, this may be due to the difference in age ranges
between the WS and TD groups (Table 1), and further
investigation of age-related volume in WS in a larger
study, ideally with longitudinal data, is warranted.
As a secondary exploratory analysis in the DS cohort
only, regions with significant age-related changes (in DS
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ation with DLD-SOS, DLD-SCS and APOE ε4 status. We
observed a strong relationship between ILV volume and
both the cognitive and social scores on the DLD, a test that
measures dementia-related impairments in the DS popula-
tion, though only the relationship between RILV and DLD-
SCS and between LILV and DLD-SOS remained nominally
significant after the one DS outlier was removed. While
we have collected data from DS study participants using a
comprehensive battery of tests, we do not have the clinical
expertise and have not sought consensus from clinical ex-
perts to determine clinical dementia status. Instead, we
have used the DLD scores as a quantitative proxy measure
of behavioral symptoms related to dementia status. Pre-
vious studies have shown that individuals with DS have
decreased regional brain volumes with onset of dementia
[50,52,53,56], and in the current study, we observed that
higher levels of dementia symptomology (as measured by
the DLD) were associated with greater ventricular volume,
an MRI biomarker of neurodegeneration.
APOE is a very strong genetic risk factor predisposing
patients to AD-associated neurodegeneration; TD adults
who are carriers of the ε4 risk allele show more signs of
neurodegeneration before symptom onset [57]. While
APOE is also known to be associated with further in-
creased risk of AD in the DS population, to our know-
ledge, this is the first study in DS to investigate the
association of APOE ε4 carrier status with MRI volume
data [39]. The observed ε4 carrier frequency was 3/28
alleles, or 11%, which is similar to the frequency ob-
served in the general population (13%). However, one of
the three ε4 carriers was the DS group outlier, and it
was this subject whose data drove the observed effect
on brain volume by APOE genotype. Thus, we are not
able to make a strong conclusion based on these data,
and future analyses with larger sample sizes will be ne-
cessary to confirm an effect of APOE on age-related
differences in brain volume in DS.
The present results must be interpreted within the
framework of our statistical models. The WS and DS
groups differed in mean age, but in all cases, we in-
cluded age and sex as important covariates known to
be related to neurodegeneration. The highly significant
P-values we observed seem to be driven in part by one
DS outlier, but the trends did not change when the
outliers were removed (Additional file 1: Figure S1).
Furthermore, though this study found a significant age-
related difference in DS adults in AD-related regions,
we may have been underpowered to detect more subtle
AD-related changes due to 1) the relatively small sam-
ple size of the DS group, 2) the strict statistical thresh-
old used for significance, and 3) the fact that FreeSurfer
parameter estimates for smaller subcortical areas, such
as the entorhinal cortex and hippocampus, are knownto exhibit greater error [58]. Despite this, some AD-
related regions were nominally significant at an un-
adjusted P < .05 (left hippocampus: P = .0023, right
amygdala: P = .0042, left amygdala: P = .0042, right pos-
terior cingulate gyrus: P = .0279, left posterior cingu-
late gyrus: P = .0495). These results warrant further
analysis of age-related affects in AD-related regions in
a larger cohort of DS adults.Conclusion
In conclusion, individuals with DS demonstrated a
unique pattern of age-related effects on gray matter and
ventricular volume, the latter of which was associated
with dementia rating scores in the DS group. Results
may indicate that early onset of brain aging in DS is pri-
marily due to DS-specific neurodegenerative processes,
as opposed to general atypical neurodevelopment.Additional file
Additional file 1: Table S1a. Regions of interest included in analysis.
Table S1b. Regions of interest not included in analysis. Table S2.
Additional demographics for Down syndrome participants, including
APOE ε4 genotype, test scores for the Dementia Questionnaire for People
with Learning Disabilities (DLD) (sum of cognitive scores (SCS) and sum
of social scores (SOS)), and the Kaufman Brief Intelligence Test (KBIT)
composite score. Table S3. complete results from analysis of relationship
between volume and age comparing the Down syndrome (DS) and
Williams syndrome (WS) groups to the typically developing (TD) controls.
Table S4. Results from analysis comparing relationship between volume
and age between participants with Down syndrome and Williams
syndrome. Table S5. To investigate whether the observed effects were
being driven by outliers, we removed the subjects whose ICV-corrected
total gray matter volume was outside of two standard deviations of the
grand mean and re-ran our analyses. Figure S1. This figure shows results
from post hoc analyses which excluded subjects whose ICV-normalized
gray matter volumes fell outside two standard deviations of the grand
mean for their respective group (one with DS and four with WS). Figure S2.
regional brain volumes normalized to ICV are plotted in relationship to
Dementia Questionnaire for People with Learning Disabilities (DLD) sum of
cognitive scores (SCS) across the Down syndrome subject group in: (a)
right inferior lateral ventricle (RILV) and (b) left inferior lateral ventricle
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in relationship to Dementia Questionnaire for People with Learning
Disabilities (DLD) sum of social scores (SOS) across the Down syndrome
subject group in: (a) right inferior lateral ventricle (RILV) and (b) left
inferior lateral ventricle (LILV). Figure S4. While APOE ε4 carrier status
showed a trend for association with regional brain volume, a larger
sample size will be needed to accurately estimate this effect.Abbreviations
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